OBJECTIVE: We conducted a population-based case-control study to investigate the association between hormone therapy (HT) and ovarian cancer incidence, and followed all these cancer cases to determine the association of HT use with ovarian cancer mortality. METHODS: Seven hundred fifty-one incident cases of invasive epithelial ovarian cancer aged 40-79 years were diagnosed in Massachusetts and Wisconsin between 1993-1995 and 1998-2001 and matched to similarly aged controls (n = 5,808). Study subjects were interviewed by telephone, which ascertained information on HT use and specific preparation, estrogen alone (E-alone) or estrogen plus progestin (EP). Ovarian cancer cases were followed-up for mortality through December 2005. Multivariate logistic regression was used to estimate odds ratios and 95% confidence intervals (CI) for ovarian cancer incidence, and Cox proportional hazards modeling was used to estimate hazard ratios and corresponding confidence intervals for ovarian cancer mortality. RESULTS: Ever use of HT was significantly associated with an increased risk of ovarian cancer (odds ratio 1.57, 95% CI 1.31-1.87). The excess risk was confined to women who used E-alone preparations (OR 2.33, 95% CI 1.85-2.95). No significant associations were detected between pre-diagnosis HT use and ovarian cancer survival. CONCLUSIONS: Hormone therapy increases risk of ovarian cancer among E-alone users, but there is no substantial impact on survival after diagnosis.
OBJECTIVE: We conducted a population-based case-control study to investigate the association between hormone therapy (HT) and ovarian cancer incidence, and followed all these cancer cases to determine the association of HT use with ovarian cancer mortality. METHODS: Seven hundred fifty-one incident cases of invasive epithelial ovarian cancer aged 40-79 years were diagnosed in Massachusetts and Wisconsin between 1993-1995 and 1998-2001 and matched to similarly aged controls (n = 5,808). Study subjects were interviewed by telephone, which ascertained information on HT use and specific preparation, estrogen alone (E-alone) or estrogen plus progestin (EP). Ovarian cancer cases were followed-up for mortality through December 2005. Multivariate logistic regression was used to estimate odds ratios and 95% confidence intervals (CI) for ovarian cancer incidence, and Cox proportional hazards modeling was used to estimate hazard ratios and corresponding confidence intervals for ovarian cancer mortality. RESULTS: Ever use of HT was significantly associated with an increased risk of ovarian cancer (odds ratio 1.57, 95% CI 1.31-1.87). The excess risk was confined to women who used E-alone preparations (OR 2.33, 95% CI 1.85-2.95). No significant associations were detected between pre-diagnosis HT use and ovarian cancer survival. CONCLUSIONS: Hormone therapy increases risk of ovarian cancer among E-alone users, but there is no substantial impact on survival after diagnosis.
Authors: Lauren C Peres; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Sarah E Abbott; Fabian Camacho; Frances Wang; Joellen M Schildkraut Journal: Am J Epidemiol Date: 2017-07-01 Impact factor: 4.897
Authors: Katharine K Brieger; Siri Peterson; Alice W Lee; Bhramar Mukherjee; Kelly M Bakulski; Aliya Alimujiang; Hoda Anton-Culver; Michael S Anglesio; Elisa V Bandera; Andrew Berchuck; David D L Bowtell; Georgia Chenevix-Trench; Kathleen R Cho; Daniel W Cramer; Anna DeFazio; Jennifer A Doherty; Renée T Fortner; Dale W Garsed; Simon A Gayther; Aleksandra Gentry-Maharaj; Ellen L Goode; Marc T Goodman; Holly R Harris; Estrid Høgdall; David G Huntsman; Hui Shen; Allan Jensen; Sharon E Johnatty; Susan J Jordan; Susanne K Kjaer; Jolanta Kupryjanczyk; Diether Lambrechts; Karen McLean; Usha Menon; Francesmary Modugno; Kirsten Moysich; Roberta Ness; Susan J Ramus; Jean Richardson; Harvey Risch; Mary Anne Rossing; Britton Trabert; Nicolas Wentzensen; Argyrios Ziogas; Kathryn L Terry; Anna H Wu; Gillian E Hanley; Paul Pharoah; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce Journal: Gynecol Oncol Date: 2020-07-06 Impact factor: 5.482
Authors: Karen J Wernli; Ellen S O'Meara; Karla Kerlikowske; Diana L Miglioretti; Carolyn Y Muller; Tracy Onega; Brian L Sprague; Louise M Henderson; Diana S M Buist Journal: J Natl Cancer Inst Date: 2013-12-05 Impact factor: 13.506
Authors: Ashley S Felix; Kristen Bunch; Hannah P Yang; Hannah Arem; Britton Trabert; Gretchen L Gierach; Yikyung Park; William J Lowery; Louise A Brinton Journal: Gynecol Oncol Rep Date: 2015-05-08
Authors: Amy L Shafrir; Ana Babic; Rulla M Tamimi; Bernard A Rosner; Shelley S Tworoger; Kathryn L Terry Journal: Br J Cancer Date: 2016-10-04 Impact factor: 7.640
Authors: Yang Liu; Lan Ma; Xiaoling Yang; Jia Bie; Dongya Li; Chunyi Sun; Jie Zhang; Yushi Meng; Jie Lin Journal: Front Endocrinol (Lausanne) Date: 2019-12-03 Impact factor: 5.555
Authors: Jelena Bešević; Marc J Gunter; Renée T Fortner; Konstantinos K Tsilidis; Elisabete Weiderpass; N Charlotte Onland-Moret; Laure Dossus; Anne Tjønneland; Louise Hansen; Kim Overvad; Sylvie Mesrine; Laura Baglietto; Françoise Clavel-Chapelon; Rudolf Kaaks; Krasimira Aleksandrova; Heiner Boeing; Antonia Trichopoulou; Pagona Lagiou; Christina Bamia; Giovanna Masala; Claudia Agnoli; Rosario Tumino; Fulvio Ricceri; Salvatore Panico; H Bas Bueno-de-Mesquita; Petra H Peeters; Mie Jareid; J Ramón Quirós; Eric J Duell; María-José Sánchez; Nerea Larrañaga; María-Dolores Chirlaque; Aurelio Barricarte; Joana A Dias; Emily Sonestedt; Annika Idahl; Eva Lundin; Nicholas J Wareham; Kay-Tee Khaw; Ruth C Travis; Sabina Rinaldi; Isabelle Romieu; Elio Riboli; Melissa A Merritt Journal: Br J Cancer Date: 2015-11-10 Impact factor: 7.640